Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib [Yahoo! Finance]
Certara, Inc. (CERT)
Company Research
Source: Yahoo! Finance
Certara Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money. RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp ® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug application (NDA) for asciminib (Scemblix ® ). PBPK modeling uses virtual biological systems to predict how drugs are absorbed, distributed, metabolized, and eliminated by the body, and is increasingly being applied in place of certain clinical studies where appropriate. The results published in “ Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib ” (Loisios-Konstantinidis et al.), highlight the growing impact and business be
Show less
Read more
Impact Snapshot
Event Time:
CERT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERT alerts
High impacting Certara, Inc. news events
Weekly update
A roundup of the hottest topics
CERT
News
- Certara (CERT) had its "equal weight" rating reaffirmed by Barclays PLC. They now have a $8.00 price target on the stock.MarketBeat
- Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminibGlobeNewswire
- Assessing Certara (CERT) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Certara (CERT) had its price target lowered by Barclays PLC from $13.00 to $8.00. They now have an "overweight" rating on the stock.MarketBeat
- Certara (CERT) was downgraded by Craig Hallum from "buy" to "hold". They now have a $10.00 price target on the stock.MarketBeat
CERT
Earnings
- 2/26/26 - Beat
CERT
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 3
- 2/26/26 - Form 10-K
- CERT's page on the SEC website